What you can learn from this “PoopTech” startup 

The bacteria in our gut affect our lives and our health in ways we are just starting to fully realize, and mapping this biome is expected to advance medical science and pharmacology as mapping the human genome. However, our gut biota is not a mappable sequence, but a complex ecosystem, and one that may be unique to each individual. In our conversation, Shinji Fukuda, founder of Metabologenomic (aka Metagen), explains how the science is advancing, what kinds of consumer devices we are likely to see first, the importance of global expansion, and the challenges of being a deep-tech startup in Japan. It's a great conversation, and I think you'll enjoy it. Show Notes What Metagen is really trying to do Fecal transplants in Japan Japan's Gut design project - a database of poop The biggest business model challenge for Japan's deep-tech startuups Smart toilets and other consumer products Why Metagen has been turning down VC money Why global expansion is critical for both business and scientific reasons Some advice for Japanese deep-tech startups Why academics need startup founders Why Japanese startups need to stop playing defense Links from the Founder Everything you ever wanted to know about Metagen Metagen on LinkedIn Transcript Welcome to Disrupting Japan, straight talk from Japan's most successful entrepreneurs. I’m Tim Romero and thanks for joining me. Today, we're going to talk about the future of poop, and I promise you that it is both a lot more interesting and also a lot less, well, strange than you might think.  Shinji Fukuda is the founder and CEO of Metabologenomics, a startup which is usually, and thankfully, referred to as Metagen. Shinji and Metagen are mapping out the complex biome of the human digestive tract.  Our gut biome is an incredibly complex ecosystem that exists within all of us, and it is an ecosystem. These bacteria don't share our DNA and they're not simply along for the ride. We couldn't function without them, and there's a lot of variation between cultures and between individuals.  Metagen is now working with some of Japan's largest healthcare, pharmaceutical, and chemical companies to commercialize this research. Of course, Metagen is not the only startup in this space, and Shinji and I talk a lot about when and how this tech is going to roll out to consumers, some of the scam startups that are already trying to get into this bandwagon, and we dive deep into one of the biggest problems facing deep tech startups in Japan.  But you know, Shinji tells that story much better than I can, so let's get right to the interview. Interview Tim: So, I'm sitting here with Shinji Fukuda of Metabologenomic who's researching and monetizing the gut biota, so thanks for sitting down with us. Shinji: Hi. Tim: And by the way, is it okay if we call the company Metagen the way people tend to do in Japanese? Shinji: Yeah, Metagen. Tim: Okay, good. So, listen, I think you can explain this much better than I can, so what exactly does Metagen do? Shinji: Our goal is to create the digital society, so we have a huge number of microbes in the gut and the gut microbiota has a lot of function, and maybe you know it's very important that the imbalance in the gut microbiota are related to some disorders like colon cancer, inflammatory bio-disorders, and also, the microbiota induce some systemic disorders like metabolic disorders and also meta-disease. That's why gut microbiota is really important to keep our health. Tim: It's amazing the amount of research that's being done on this right now and it's still a relatively new field. So, for Metagen, what is the main goal of the company? Are you trying to develop more targeted medicine? Is it better food? Is it a healthier population? What is it that the company is focused on? Shinji: Here, actually, everything, but we have a priority. Our goal is healthcare, to develop the technology to keep our health,